August 7. 2024
(¥ million)
Brand name | Active Ingredient | Indications | Launch Date |
Sales 2022 (IFRS) |
Sales 2023 (IFRS) |
Sales 2024 (IFRS) | ||
---|---|---|---|---|---|---|---|---|
Apr-Jun |
Apr-Sep (estimated) |
Annual (estimated) |
||||||
Viltepso | 14,341 | 17,530 | 5,450 | 10,300 | 20,600 | |||
(Japan) | viltolarsen |
Duchenne muscular dystrophy |
Japan May-2020 U.S. Aug-2020 |
(4,139) | (4,407) | 1,175 | 2,300 | 4,600 |
(U.S.) | (10,201) | (13,123) | 4,275 | 8,000 | 16,000 | |||
Uptravi | selexipag |
pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension |
Nov-2016/ Aug-2021 |
10,543 | 12,918 | 3,855 | 7,600 | 15,400 |
Vidaza | azacitidine |
myelodysplastic syndrome/ acute myeloid leukemia |
Mar-2011/ Mar-2021 |
15,951 | 10,383 | 1,462 | 2,600 | 4,800 |
Gazyva | obinutuzumab |
CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia |
Aug-2018/ Dec-2022 |
4,904 | 4,695 | 1,254 | 2,500 | 5,100 |
Tramal, Onetram | tramadol hydrochloride | cancer pain, chronic pain | Sep-2010 | 5,358 | 3,927 | 778 | 1,400 | 2,700 |
Defitelio | defibrotide sodium | sinusoidal obstruction syndrome | Sep-2019 | 2,524 | 2,221 | 709 | 1,100 | 2,300 |
Cialis | tadalafil | erectile dysfunction | Jul-2009 | 2,938 | 2,499 | 647 | 1,400 | 2,700 |
Zalutia | tadalafil | urinary disorder caused by benign prostatic hyperplasia | Apr-2014 | 2,826 | 2,256 | 493 | 850 | 1,600 |
Adcirca | tadalafil | pulmonary arterial hypertension | Dec-2009 | 2,649 | 2,255 | 480 | 900 | 1,700 |
Erizas | dexamethasone cipecilate | allergic rhinitis | Dec-2009 | 2,640 | 2,284 | 281 | 700 | 2,100 |
Profit in co-promotion | 9,520 | 8,658 | 2,461 | 4,550 | 9,100 | |||
Revenues from the licensing of industrial property rights | 30,714 | 40,304 | 10,779 | 21,000 | 42,100 | |||
Pharmaceuticals | 121,988 | 125,105 | 33,738 | 65,300 | 132,500 | |||
Functional Food | 22,187 | 23,150 | 5,393 | 10,500 | 21,500 | |||
Revenue | 144,175 | 148,255 | 39,131 | 75,800 | 154,000 |
Brand name | Active Ingredient | Indications | Launch Date |
Sales 2022 (IFRS) |
Sales 2023 (IFRS) |
Sales 2024 (IFRS) | ||
---|---|---|---|---|---|---|---|---|
Apr-Jun |
Apr-Sep (estimated) |
Annual (estimated) |
||||||
Viltepso | 14,341 | 17,530 | 5,450 | 10,300 | 20,600 | |||
(Japan) | viltolarsen |
Duchenne muscular dystrophy |
Japan May-2020 U.S. Aug-2020 |
(4,139) | (4,407) | 1,175 | 2,300 | 4,600 |
(U.S.) | (10,201) | (13,123) | 4,275 | 8,000 | 16,000 | |||
Uptravi | selexipag |
pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension |
Nov-2016/ Aug-2021 |
10,543 | 12,918 | 3,855 | 7,600 | 15,400 |
Vidaza | azacitidine |
myelodysplastic syndrome/ acute myeloid leukemia |
Mar-2011/ Mar-2021 |
15,951 | 10,383 | 1,462 | 2,600 | 4,800 |
Gazyva | obinutuzumab |
CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia |
Aug-2018/ Dec-2022 |
4,904 | 4,695 | 1,254 | 2,500 | 5,100 |
Tramal, Onetram | tramadol hydrochloride | cancer pain, chronic pain | Sep-2010 | 5,358 | 3,927 | 778 | 1,400 | 2,700 |
Defitelio | defibrotide sodium | sinusoidal obstruction syndrome | Sep-2019 | 2,524 | 2,221 | 709 | 1,100 | 2,300 |
Cialis | tadalafil | erectile dysfunction | Jul-2009 | 2,938 | 2,499 | 647 | 1,400 | 2,700 |
Zalutia | tadalafil | urinary disorder caused by benign prostatic hyperplasia | Apr-2014 | 2,826 | 2,256 | 493 | 850 | 1,600 |
Adcirca | tadalafil | pulmonary arterial hypertension | Dec-2009 | 2,649 | 2,255 | 480 | 900 | 1,700 |
Erizas | dexamethasone cipecilate | allergic rhinitis | Dec-2009 | 2,640 | 2,284 | 281 | 700 | 2,100 |
Profit in co-promotion | 9,520 | 8,658 | 2,461 | 4,550 | 9,100 | |||
Revenues from the licensing of industrial property rights | 30,714 | 40,304 | 10,779 | 21,000 | 42,100 | |||
Pharmaceuticals | 121,988 | 125,105 | 33,738 | 65,300 | 132,500 | |||
Functional Food | 22,187 | 23,150 | 5,393 | 10,500 | 21,500 | |||
Revenue | 144,175 | 148,255 | 39,131 | 75,800 | 154,000 |
ending March 2024(FY2023) |
Q1PDF48 KB | Q1~2PDF46 KB | Q1~3PDF42 KB | Q1~4PDF42 KB |
---|---|---|---|---|
ending March 2023(FY2022) |
Q1PDF70 KB | Q1~2PDF61 KB | Q1~3PDF46 KB | Q1~4PDF58 KB |
ending March 2022(FY2021) |
Q1PDF44 KB | Q1~2PDF43 KB | Q1~3PDF48 KB | Q1~4PDF61 KB |
ending March 2021(FY2020) |
Q1PDF44 KB | Q1~2PDF51 KB | Q1~3PDF42 KB | Q1~4PDF43 KB |
ending March 2020(FY2019) |
Q1PDF43 KB | Q1~2PDF42 KB | Q1~3PDF43 KB | Q1~4PDF43 KB |
Business/Financial Information
- Business Highlights
- Consolidated Financial Statements
- Product Development
- Leading Product Revenue